ClinicalTrials.gg
CompletedNCT06482112Updated Jun 1, 2026Results posted

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

A Phase 2 interventional study of Efinopegdutide in Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 39 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.

Enrollment
5th of 10
124 · median 113
Started
2024
with 1 other
Phase 2
7 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 in phase 2, and was the 11th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc as a file.
02

Study summary

This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.

03

Conditions studied

  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Non-alcoholic Fatty Liver Disease
  • Nonalcoholic Fatty Liver Disease
  • Liver Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has (BMI) ≥25 kg/m\^2 (≥23 kg/m\^2 for Asian participants) AND has stable weight, defined as ≤5% gain or loss of body weight for at least 3 months before screening
  • Has no history of type 2 diabetes mellitus (T2DM) OR has a history of T2DM with a (A1C) ≤9% AND the T2DM is controlled by diet or stable doses of oral antihyperglycemic agents (AHAs)

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following

  • Has a history or evidence of chronic liver disease other than Metabolic dysfunction-associated steatotic liver disease (MASLD) or Metabolic dysfunction-associated steatohepatitis (MASH)
  • Has evidence of decompensated liver disease including, but not limited to ascites, esophageal or gastric variceal bleeding, hepatocellular carcinoma, hepatic encephalopathy, splenomegaly, or spontaneous bacterial peritonitis
  • Has a history of pancreatitis
  • Has a history of type 1 diabetes mellitus (T1DM), diabetic ketoacidosis, or diabetes secondary to pancreatectomy.
  • Has symptomatic hyperglycemia
  • Has a history of a bariatric surgical procedure ≤5 years before Screening or a known gastric emptying abnormality
  • Has a history of obesity with a known secondary cause
  • Has significant systemic or major illnesses, including recent (≤6 months before Screening) onset of events of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or
  • Is unable to have Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF) due to: Claustrophobia to a degree that prevents tolerance of an MRI-PDFF scanning procedure. Note: Sedation is permitted, at the discretion of the investigator; Metallic implants that prevent MRI-PDFF examination; Exceeds the body habitus and/or weight limitations for the MRI scanner
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Active comparator
    Efinopegdutide Q1W 10 mg

    Participants will receive efinopegdutide Q1W via subcutaneous (SC) injection for 28 weeks in a dose-escalating regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for up to 16 weeks.

    Drug: Efinopegdutide

  • Experimental
    Efinopegdutide Q2W 10 mg

    Participants will receive efinopegdutide Q2W via SC injection for 28 weeks in a dose-escalating regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for up to 16 weeks.

    Drug: Efinopegdutide

  • Experimental
    Efinopegdutide Q2W 15 mg

    Participants will receive efinopegdutide Q2W via SC injection for 28 weeks in a dose-escalating regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, 10 mg for 4 weeks, and 15 mg for up to 12 weeks.

    Drug: Efinopegdutide

Interventions

  • SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm

    Also known as: MK-6024, HM12525A, JNJ-64565111

06

What researchers measure

Primary outcomes

  1. Mean Relative Reduction From Baseline in Liver Fat Content at Week 28

    Liver fat content (LFC) was measured with liver images taken by magnetic resonance imaging estimated proton density fat fraction (MRI-PDFF) and analyzed by blinded independent central review (BICR). Relative Reduction from Baseline to Week 28 = (Baseline - Week 28) / Baseline x 100%. Least Squares (LS) Mean relative reduction from baseline in LFC is presented.

    Time frame: Baseline and Week 28

  2. Percentage of Participants Who Experienced an Adverse Event (AE)

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who experienced an AE is presented.

    Time frame: Up to Week 32

  3. Percentage of Participants Who Discontinued Study Intervention Due to an AE

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who discontinued study intervention due to an AE is presented.

    Time frame: Up to Week 28

Secondary outcomes

  1. Mean Percent Change From Baseline in Body Weight at Week 28

    Body weight in kilograms was measured using a standardized, digital scale. Mean percent change in body weight from Baseline to Week 28 = (Week 28 - Baseline) / Baseline x 100%. The LS mean percent change from baseline in body weight at 28 weeks is presented.

    Time frame: Baseline and Week 28

07

Results

Posted Jun 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneEfinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mg
Started424042
Treated423942
Completed393534
Not completed358
Withdrew: Exclusionary laboratory result010
Withdrew: Withdrawal by subject214
Withdrew: Physician decision111
Withdrew: Lost to follow-up023

Outcome measures

PrimaryMean Relative Reduction From Baseline in Liver Fat Content at Week 28

Liver fat content (LFC) was measured with liver images taken by magnetic resonance imaging estimated proton density fat fraction (MRI-PDFF) and analyzed by blinded independent central review (BICR). Relative Reduction from Baseline to Week 28 = (Baseline - Week 28) / Baseline x 100%. Least Squares (LS) Mean relative reduction from baseline in LFC is presented.

Time frame:
Baseline and Week 28
Reported as:
Least squares mean · Percent Reduction
Mean Relative Reduction From Baseline in Liver Fat Content at Week 28
Percent ReductionEfinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mg
Mean Relative Reduction From Baseline in Liver Fat Content at Week 2867.8 (60.7 to 74.9)54.4 (46.8 to 61.9)42.1 (34.6 to 49.5)
PrimaryPercentage of Participants Who Experienced an Adverse Event (AE)

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who experienced an AE is presented.

Time frame:
Up to Week 32
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced an Adverse Event (AE)
Percentage of participantsEfinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mg
Percentage of Participants Who Experienced an Adverse Event (AE)83.382.185.7
PrimaryPercentage of Participants Who Discontinued Study Intervention Due to an AE

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who discontinued study intervention due to an AE is presented.

Time frame:
Up to Week 28
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Intervention Due to an AE
Percentage of participantsEfinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mg
Percentage of Participants Who Discontinued Study Intervention Due to an AE7.15.19.5
SecondaryMean Percent Change From Baseline in Body Weight at Week 28

Body weight in kilograms was measured using a standardized, digital scale. Mean percent change in body weight from Baseline to Week 28 = (Week 28 - Baseline) / Baseline x 100%. The LS mean percent change from baseline in body weight at 28 weeks is presented.

Time frame:
Baseline and Week 28
Reported as:
Least squares mean · Percent Change
Mean Percent Change From Baseline in Body Weight at Week 28
Percent ChangeEfinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mg
Mean Percent Change From Baseline in Body Weight at Week 28-7.5 (-8.8 to -6.1)-3.9 (-5.3 to -2.5)-4.1 (-5.5 to -2.7)

Adverse events

Collected over Up to Week 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efinopegdutide Q1W 10 mg0/42 (0%)3/42 (7.1%)30/42 (71.4%)
Efinopegdutide Q2W 10 mg0/40 (0%)2/39 (5.1%)27/39 (69.2%)
Efinopegdutide Q2W 15 mg0/42 (0%)4/42 (9.5%)33/42 (78.6%)
Most frequent serious events
Most frequent serious events
EventEfinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mg
Ankle fractureInjury, poisoning and procedural complications1/421/390/42
Lumbar radiculopathyNervous system disorders0/421/390/42
Supraventricular tachycardiaCardiac disorders0/420/391/42
VomitingGastrointestinal disorders1/420/390/42
AppendicitisInfections and infestations0/420/391/42
BacteraemiaInfections and infestations0/420/391/42
Diabetic ketoacidosisMetabolism and nutrition disorders1/420/390/42
CholecystitisHepatobiliary disorders0/420/391/42
Most frequent other events
Showing 10 of 24
Most frequent other events
EventEfinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mg
NauseaGastrointestinal disorders14/4213/3920/42
ConstipationGastrointestinal disorders11/428/3912/42
DiarrhoeaGastrointestinal disorders9/423/396/42
VomitingGastrointestinal disorders8/427/399/42
HeadacheNervous system disorders9/422/395/42
Injection site painGeneral disorders5/421/398/42
Decreased appetiteMetabolism and nutrition disorders7/426/395/42
Gastrooesophageal reflux diseaseGastrointestinal disorders6/421/394/42
DizzinessNervous system disorders2/421/396/42
Abdominal distensionGastrointestinal disorders5/420/391/42

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Efinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mgTotal
Mean47.6 ± 11.953.4 ± 12.650.8 ± 13.850.6 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Efinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mgTotal
Female27222877
Male15181447
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Efinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mgTotal
Hispanic or Latino28232879
Not Hispanic or Latino14171344
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Efinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mgTotal
American Indian or Alaska Native0000
Asian0202
Native Hawaiian or Other Pacific Islander0000
Black or African American43411
White373238107
More than one race1102
Unknown or Not Reported0202
Weight
Weight(kg)Efinopegdutide Q1W 10 mgEfinopegdutide Q2W 10 mgEfinopegdutide Q2W 15 mgTotal
Mean105.5 ± 21.2108.4 ± 24.4101.8 ± 20.7105.2 ± 22.1
08

Study locations

39 sites
  • The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0
    Chandler, Arizona 85224, United States
  • The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0224)
    Peoria, Arizona 85381, United States
  • Arizona Liver Health ( Site 0211)
    Tucson, Arizona 85712, United States
  • Del Sol Research Management, LLC ( Site 0209)
    Tucson, Arizona 85715, United States
  • Om Research LLC ( Site 0207)
    Camarillo, California 93012, United States
  • Gastroenterology and Liver Institute ( Site 0263)
    Escondido, California 92025, United States
  • Velocity Clinical Research, Gardena ( Site 0235)
    Gardena, California 90247, United States
  • Velocity Clinical Research, Huntington Park ( Site 0210)
    Huntington Park, California 90255, United States
  • California Liver Research Institute ( Site 0216)
    Pasadena, California 91105, United States
  • Acclaim Clinical Research ( Site 0241)
    San Diego, California 92120, United States
  • Velocity Clinical Research, Santa Ana ( Site 0250)
    Santa Ana, California 92704, United States
  • Velocity Clinical Research, Panorama City ( Site 0228)
    Van Nuys, California 91405, United States
  • Excel Medical Clinical Trials ( Site 0268)
    Boca Raton, Florida 33434, United States
  • AGA Clinical Trials ( Site 0274)
    Hialeah, Florida 33012, United States
  • Neoclinical Research ( Site 0275)
    Hialeah, Florida 33016, United States
  • Homestead Associates in Research, Inc. ( Site 0243)
    Homestead, Florida 33033, United States
  • Floridian Clinical Research, LLC ( Site 0208)
    Miami Lakes, Florida 33016, United States
  • Southeast Clinical Research Center ( Site 0223)
    Dalton, Georgia 30720, United States
  • Velocity Clinical Research Rockville ( Site 0245)
    Rockville, Maryland 20854, United States
  • The Machuca Foundation ( Site 0218)
    Las Vegas, Nevada 89101, United States
  • Excel Clinical Research, LLC ( Site 0200)
    Las Vegas, Nevada 89109, United States
  • Basil Clinical ( Site 0246)
    Inwood, New York 11096, United States
  • Lucas Research, Inc ( Site 0204)
    Morehead City, North Carolina 28557, United States
  • Texas Clinical Research Institute ( Site 0230)
    Arlington, Texas 76012, United States
  • Pinnacle Clinical Research ( Site 0203)
    Austin, Texas 78757, United States
  • Velocity Clinical Research, Austin ( Site 0201)
    Austin, Texas 78759, United States
  • Pinnacle Clinical Research-Corpus Christi ( Site 0267)
    Corpus Christi, Texas 78404, United States
  • Zenos Clinical Research ( Site 0240)
    Dallas, Texas 75230, United States
  • South Texas Research Institute ( Site 0226)
    Edinburg, Texas 78539, United States
  • Houston Research Institute ( Site 0221)
    Houston, Texas 77079, United States
  • American Research Corporation ( Site 0234)
    San Antonio, Texas 78215, United States
  • Clinical Trials of Texas, LLC-Clinical Research ( Site 0252)
    San Antonio, Texas 78229, United States
  • Pinnacle Clinical Research-Clinical Research Coordination ( Site 0229)
    San Antonio, Texas 78229, United States
  • Impact Research Institute ( Site 0227)
    Waco, Texas 76710, United States
  • Olympus Family Medicine/CCT Research ( Site 0266)
    Holladay, Utah 84117, United States
  • South Ogden Family Medicine/ CCT Research ( Site 0255)
    South Ogden, Utah 84405, United States
  • San Juan Bautista School of Medicine - Clinical Research Unit ( Site 0104)
    Caguas, 00726, Puerto Rico
  • Klinical Investigations Group-Clinical Research ( Site 0100)
    San Juan, 00909, Puerto Rico
  • Pan American Center for Oncology Trials - Ciudadela ( Site 0101)
    San Juan, 00909, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jun 2025, 10 months.

Results were first posted in Jun 2026, 11 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 10 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 1, 2024
StartActual
Jul 29, 2024
Primary completionActual
Jun 27, 2025
CompletionActual
Jun 27, 2025
Results first posted
Jun 1, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06482112
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Jul 29, 2024
Primary completion
Jun 27, 2025
Completion
Jun 27, 2025
Results posted
Jun 1, 2026
Last update
Jun 1, 2026

Study contacts

Medical Director
study director · Merck Sharp and Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion